HC Wainwright Initiates Coverage on Perspective Therapeutics (NYSE:CATX) with Positive Outlook

On Thursday, HC Wainwright announced the initiation of coverage on shares of Perspective Therapeutics (NYSE:CATX). In their research note, the analysts assigned a "buy" rating to the stock, along with a target price of $10.00. This target suggests a potential upside of 275.94% from its previous closing price.

Other financial institutions have also looked into Perspective Therapeutics, with varying opinions on its stock. For instance, Scotiabank began coverage on March 7th with a "sector outperform" rating and a price target of $15.00. Meanwhile, Cantor Fitzgerald upgraded the stock to a "strong-buy" rating earlier in March, while the Royal Bank of Canada maintained an "outperform" rating with a target price of $16.00. Oppenheimer lowered their price target from $22.00 to $16.00 but still rated the stock as "outperform". Lastly, Lifesci Capital confirmed a "strong-buy" rating for Perspective Therapeutics in another report.

Overall, the stock has received a mix of ratings, with one research analyst assigning a hold rating, while eight analysts recommend a buy, and three suggest a strong buy. Based on a consensus from MarketBeat, Perspective Therapeutics holds a "Buy" rating, with an average target price of $14.56.

Stock Performance Overview

Perspective Therapeutics shares opened at $2.66 on Thursday. The stock has seen fluctuations over the past year, hitting a low of $2.32 and a high of $19.05. Currently, the 50-day moving average stands at $3.17, while the 200-day moving average is at $7.44.

Institutional Investors Activity

Several institutional investors and hedge funds have recently adjusted their positions in Perspective Therapeutics. The Manufacturers Life Insurance Company increased its stake by 8.9% in the third quarter, owning 20,514 shares valued at approximately $274,000. UBS Asset Management Americas also raised its stake by 5.8% in the same quarter, holding 58,678 shares worth about $783,000.

BNP Paribas Financial Markets increased its position by 7.4%, now owning 51,094 shares valued at $163,000. Additionally, US Bancorp DE saw a significant jump in its stake by 142.7%, owning 6,576 shares valued at $88,000. Rhumbline Advisers also increased their position by 4.5%, ending up with 94,992 shares worth around $303,000. Collectively, institutional investors now own 54.66% of Perspective Therapeutics' stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc. focuses on developing precision-targeted alpha therapies (TAT) aimed at treating cancer across various tumor types, including metastatic disease. Their current programs include VMT-a-NET, which is undergoing Phase 1/2a clinical trials for patients with unresectable or metastatic tumors that express somatostatin receptor type 2 (SSTR2). Another candidate, VMT01, is also in Phase 1/2a trials aimed at treating advanced melanocortin 1 receptor (MC1R) positive metastatic melanoma.

stocks, research, investing